See more : DevEx Resources Limited (UREQF) Income Statement Analysis – Financial Results
Complete financial analysis of Qualigen Therapeutics, Inc. (QLGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Qualigen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aviva plc (AVVIY) Income Statement Analysis – Financial Results
- Garuda Construction and Engineering Limited (GARUDA.NS) Income Statement Analysis – Financial Results
- Beijing Huayuanyitong Thermal Technology Co., Ltd. (002893.SZ) Income Statement Analysis – Financial Results
- Koramco Energy Plus Reit (357120.KS) Income Statement Analysis – Financial Results
- Theta Gold Mines Limited (TGMGF) Income Statement Analysis – Financial Results
Qualigen Therapeutics, Inc. (QLGN)
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20M | 4.98M | 5.65M | 4.31M | 5.56M | 5.80M | 9.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.21M | 4.30M | 4.33M | 7.19M | 3.98M | 5.42M | 7.90M | 18.45M | 8.91M | 3.48K | 2.14K | 758.00 |
| Gross Profit | -4.50K | 680.80K | 1.32M | -2.88M | 1.58M | 378.39K | 1.87M | -18.45M | -8.91M | -3.48K | -2.14K | -758.00 |
| Gross Profit Ratio | -0.09% | 13.66% | 23.37% | -66.87% | 28.43% | 6.52% | 19.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 6.84M | 11.72M | 3.55M | 1.21M | 1.32M | 2.87M | 13.29M | 2.26M | 113.93K | 461.55K | 1.39M |
| General & Administrative | 6.10M | 10.84M | 11.72M | 8.02M | 1.51M | 1.05M | 4.78M | 4.88M | 6.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -4.50K | 950.42K | 542.59K | 400.17K | 367.95K | 380.34K | 618.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09M | 11.79M | 12.27M | 8.42M | 1.88M | 1.43M | 4.78M | 4.88M | 6.40M | 2.16M | 1.65M | 2.01M |
| Other Expenses | -5.21M | 1.13K | 5.45K | 0.00 | 2.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.10M | 18.62M | 23.98M | 17.40M | 3.08M | 1.42M | 7.65M | 18.17M | 8.66M | 2.28M | 2.11M | 3.40M |
| Cost & Expenses | 11.30M | 22.93M | 28.32M | 24.59M | 7.06M | 6.85M | 15.55M | 36.62M | 17.57M | 2.28M | 2.11M | 3.40M |
| Interest Income | 0.00 | 26.65K | 42.69K | 138.80K | 123.05B | 152.04K | 40.23K | 60.88K | 40.88K | 525.00 | 1.68K | 2.91K |
| Interest Expense | 1.52M | 26.65K | 0.00 | 0.00 | 283.10K | 0.00 | 0.00 | 0.00 | 0.00 | 213.52K | 6.08K | 54.64K |
| Depreciation & Amortization | 4.50K | 12.17K | 322.06K | 138.65K | 111.38K | 5.70K | 5.70K | 5.21K | 1.94K | 3.48K | 2.14K | 758.00 |
| EBITDA | -11.30M | -13.84M | -22.66M | -11.16M | -10.02M | -717.86K | -7.86M | -18.38M | -8.79M | -2.26M | -2.09M | -3.40M |
| EBITDA Ratio | -217.12% | -285.64% | -478.41% | -259.27% | -23.10% | -12.37% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.30M | -17.94M | -22.66M | -11.30M | -1.50M | -1.06M | -15.55M | -36.62M | -17.57M | -2.28M | -2.11M | -3.40M |
| Operating Income Ratio | -217.20% | -360.03% | -400.85% | -262.49% | -27.05% | -18.18% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.17M | 872.81K | 4.77M | -7.74M | 711.17K | -140.55K | 38.60K | 18.24M | 8.79M | -191.85K | 14.97K | -51.73K |
| Income Before Tax | -12.48M | -21.30M | -17.89M | -20.42M | -1.78M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Income Before Tax Ratio | -239.78% | -427.40% | -316.46% | -474.18% | -32.09% | -20.61% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -4.79K | -265.07K | 5.43K | 619.00 | 4.00K | 4.62K | 5.09K | -5.21K | -1.94K | 1.00 | 0.00 | 0.00 |
| Net Income | -13.42M | -21.03M | -17.90M | -20.42M | -1.79M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Net Income Ratio | -257.79% | -422.08% | -316.55% | -474.16% | -32.16% | -20.69% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| EPS Diluted | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| Weighted Avg Shares Out | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
| Weighted Avg Shares Out (Dil) | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
Qualigen Therapeutics Divests FastPack® Diagnostics Business
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeutics
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing...
Qualigen Therapeutics to Present at BIO International Convention
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that...
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that...
Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.
Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers
Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR). QN-302 showed potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo metastatic.
Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022
Check these three Reddit penny stocks out for your watchlist next year The post Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information |...
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
Source: https://incomestatements.info
Category: Stock Reports